Collplant Biotechnologies is a regenerative and aesthetic medicine company focused on three dimensional (3D) bioprinting of tissues and organs, and medical aesthetics. Co.'s products and product candidates are based on its recombinant human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. Co.'s two rhCollagen-based family products lines are: CollPlant rhCollagen-based BioInk for use in the 3D printing of tissues and organs; and aesthetic medicine product line including a dermal filler and breast implants. Co. also markets two of its products in Europe: VergenixSTR, a soft tissue matrix, and VergenixFG, a wound healing flowable gel. We show 1 historical shares outstanding datapoints in our CLGN shares outstanding history coverage, used to compute CLGN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CLGN market cap history over the course of time is important for investors
interested in comparing CLGN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CLGN versus a peer is one thing; comparing
CLGN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CLGN can fluctuate over the course of history.
With this page we aim to empower investors researching CLGN by allowing them to research the CLGN market cap history. |
Free CLGN Email Alerts:
Video: The Importance of Market Cap
